Patents by Inventor Markus Jerling

Markus Jerling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
    Patent number: 11026953
    Abstract: The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of essential tremor, as well as methods for treating essential tremor and pharmaceutical compositions for use in treatment of essential tremor.
    Type: Grant
    Filed: September 2, 2018
    Date of Patent: June 8, 2021
    Assignee: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Markus Jerling
  • 3-Beta-Hydroxy-5-Alpha-Pregnan-20-One for Use in Treatment of Essential Tremor
    Publication number: 20190381069
    Abstract: The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of essential tremor, as well as methods for treating essential tremor and pharmaceutical compositions for use in treatment of essential tremor.
    Type: Application
    Filed: September 2, 2018
    Publication date: December 19, 2019
    Applicant: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Markus Jerling
  • METHOD OF TREATING DIABETES
    Publication number: 20140378465
    Abstract: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 25, 2014
    Inventors: MARKUS JERLING, ANDREW A. WOLFF
  • Method of treating diabetes
    Patent number: 8883750
    Abstract: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 11, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Andrew A. Wolff, Markus Jerling
  • Method of treating diabetes
    Patent number: 8314104
    Abstract: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: November 20, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Andrew Wolff, Markus Jerling
  • METHOD OF TREATING DIABETES
    Publication number: 20100197701
    Abstract: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.
    Type: Application
    Filed: April 7, 2010
    Publication date: August 5, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Andrew Wolff, Markus Jerling
  • USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    Publication number: 20100035890
    Abstract: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.
    Type: Application
    Filed: October 15, 2009
    Publication date: February 11, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Louis Lange, Markus Jerling, Andrew Wolff
  • USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    Publication number: 20090312340
    Abstract: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.
    Type: Application
    Filed: February 12, 2009
    Publication date: December 17, 2009
    Inventors: Whedy Wang, Ewa Prokopczuk, Luiz Belardinelli, Louis Lange, Markus Jerling, Andrew Wolff
  • USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    Publication number: 20080214555
    Abstract: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.
    Type: Application
    Filed: February 13, 2008
    Publication date: September 4, 2008
    Inventor: Markus Jerling
  • USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    Publication number: 20080214556
    Abstract: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.
    Type: Application
    Filed: February 13, 2008
    Publication date: September 4, 2008
    Inventors: Markus Jerling, Andrew Wolff
  • Method of treating diabetes
    Publication number: 20040063717
    Abstract: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.
    Type: Application
    Filed: May 21, 2003
    Publication date: April 1, 2004
    Inventors: Andrew Wolff, Markus Jerling